Education
About Us
Working with TipRanks
Follow Us
Grace Therapeutics, Inc. (GRCE)
:GRCE
GRCE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.13 - $4.97
Previous CloseN/A
Volume30.96K
Average Volume (3M)100.91K
Market Cap
$40.65M
Enterprise Value$19.35M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)119.00K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Jun 24, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding13,416,735
10 Day Avg. Volume35,085
30 Day Avg. Volume100,905
Standard Deviation0.27
R-Squared0.07
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.50Price Target Upside279.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Grace Therapeutics News
PremiumCompany Announcements
Grace Therapeutics Reports Steady Progress and Financials---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressSTRIVE-ON trial completed enrollment faster than expected, indicating accelerated progress.
Regulatory StrategyAcasti secured agreement from the FDA on a streamlined approach with an open-label pivotal safety trial.
Bears Say
Safety ConcernsThere were more deaths in the GTX-104 arm compared to the oral nimodipine arm, but no deaths were attributed to nimodipine therapy.
---
Ownership Overview
―
Insiders
0.03% Mutual Funds
12.77% Other Institutional Investors
84.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GRCE FAQ
What was Grace Therapeutics, Inc.’s price range in the past 12 months?
Grace Therapeutics, Inc. lowest stock price was $2.13 and its highest was $4.96 in the past 12 months.
What is Grace Therapeutics, Inc.’s market cap?
Grace Therapeutics, Inc.’s market cap is $40.65M.
When is Grace Therapeutics, Inc.’s upcoming earnings report date?
Grace Therapeutics, Inc.’s upcoming earnings report date is Jun 24, 2025 which is in 112 days.
How were Grace Therapeutics, Inc.’s earnings last quarter?
Grace Therapeutics, Inc. released its earnings results on Feb 13, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.335 by -$0.025.
Is Grace Therapeutics, Inc. overvalued?
According to Wall Street analysts Grace Therapeutics, Inc.’s price is currently Undervalued.
Does Grace Therapeutics, Inc. pay dividends?
Grace Therapeutics, Inc. does not currently pay dividends.
What is Grace Therapeutics, Inc.’s EPS estimate?
Grace Therapeutics, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Grace Therapeutics, Inc. have?
Grace Therapeutics, Inc. has 13,416,735 shares outstanding.
What happened to Grace Therapeutics, Inc.’s price movement after its last earnings report?
Grace Therapeutics, Inc. reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.335. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Grace Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GRCE
---
Grace Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (279.54% Upside)
$11.50 (279.54% Upside)
Blogger Sentiment
Bullish
GRCE Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.88%
12-Months-Change
Fundamentals
Return on Equity
-22.89%
Trailing 12-Months
Asset Growth
-19.64%
Trailing 12-Months
Company Description
Grace Therapeutics, Inc.
Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
---
GRCE Stock 12 Month Forecast
Average Price Target
$11.50
▲(279.54% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
SAGE Therapeutics
―
Best Analysts Covering GRCE
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
+4.17%
reiterated a buy rating 22 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +4.17% per trade.
---